Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

20.35
+5.0332.83%
Pre-market: 20.350.00000.00%06:26 EDT
Volume:2.02M
Turnover:41.43M
Market Cap:590.32M
PE:-61.00
High:21.33
Open:19.85
Low:18.68
Close:15.32
Loading ...

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

GlobeNewswire
·
01 May

Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000

MT Newswires Live
·
29 Apr

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

GlobeNewswire
·
26 Apr

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

GlobeNewswire
·
08 Apr

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

GlobeNewswire
·
07 Apr

Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Simply Wall St.
·
02 Apr

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

GlobeNewswire
·
29 Mar

BTIG Keeps Their Buy Rating on Castle Biosciences (CSTL)

TIPRANKS
·
18 Mar

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire
·
07 Mar

Castle Biosciences (CSTL) Gets a Buy from Scotiabank

TIPRANKS
·
03 Mar

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Simply Wall St.
·
01 Mar

Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Mar

Q4 2024 Castle Biosciences Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
28 Feb

Castle Biosciences price target raised to $37 from $36 at Baird

TIPRANKS
·
28 Feb

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com
·
28 Feb

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Zacks
·
28 Feb

Castle Biosciences sees FY25 revenue $280M-$295M, consensus $269.06M

TIPRANKS
·
28 Feb

Castle Biosciences Q4 2024 GAAP EPS $0.32 Up From $(0.10) YoY, Sales $86.311M Beat $81.911M Estimate

Benzinga
·
28 Feb

BRIEF-Castle Biosciences Q4 Revenue USD 86.311 Million Vs. IBES Estimate USD 81.9 Million

Reuters
·
28 Feb